HRP20211908T1 - Upotreba varijanti natriuretskog peptida c-tipa za liječenje osteoartritisa - Google Patents
Upotreba varijanti natriuretskog peptida c-tipa za liječenje osteoartritisa Download PDFInfo
- Publication number
- HRP20211908T1 HRP20211908T1 HRP20211908TT HRP20211908T HRP20211908T1 HR P20211908 T1 HRP20211908 T1 HR P20211908T1 HR P20211908T T HRP20211908T T HR P20211908TT HR P20211908 T HRP20211908 T HR P20211908T HR P20211908 T1 HRP20211908 T1 HR P20211908T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- cnp variant
- seq
- nos
- use according
- Prior art date
Links
- 201000008482 osteoarthritis Diseases 0.000 title claims 11
- 102000012421 C-Type Natriuretic Peptide Human genes 0.000 title 1
- 101800000060 C-type natriuretic peptide Proteins 0.000 title 1
- 210000000845 cartilage Anatomy 0.000 claims 7
- 230000007850 degeneration Effects 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 210000003127 knee Anatomy 0.000 claims 3
- 108010041390 Collagen Type II Proteins 0.000 claims 2
- 102000000503 Collagen Type II Human genes 0.000 claims 2
- 108050006400 Cyclin Proteins 0.000 claims 2
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 claims 2
- 102000016611 Proteoglycans Human genes 0.000 claims 2
- 108010067787 Proteoglycans Proteins 0.000 claims 2
- 239000000090 biomarker Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 claims 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims 1
- 102000016284 Aggrecans Human genes 0.000 claims 1
- 108010067219 Aggrecans Proteins 0.000 claims 1
- 206010007710 Cartilage injury Diseases 0.000 claims 1
- 101800000938 Chondrocalcin Proteins 0.000 claims 1
- 229920001287 Chondroitin sulfate Polymers 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 102000012422 Collagen Type I Human genes 0.000 claims 1
- 108010022452 Collagen Type I Proteins 0.000 claims 1
- 206010060820 Joint injury Diseases 0.000 claims 1
- 102000004067 Osteocalcin Human genes 0.000 claims 1
- 108090000573 Osteocalcin Proteins 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000008351 acetate buffer Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 206010061592 cardiac fibrillation Diseases 0.000 claims 1
- 210000001612 chondrocyte Anatomy 0.000 claims 1
- 229940059329 chondroitin sulfate Drugs 0.000 claims 1
- 239000007979 citrate buffer Substances 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002600 fibrillogenic effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 210000004247 hand Anatomy 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000012931 lyophilized formulation Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000008409 synovial inflammation Effects 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
- 210000000707 wrist Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (14)
1. CNP varijanta odabrana iz skupine koju čine SEQ ID NOs.: 1, 2, 22 i 43 do 47 za uporabu u postupku i) liječenja osteoartritisa; ii) povećanja rasta hrskavice kod subjekta s osteoartritisom; iii) usporavanje degeneracije hrskavice; iv) ublažavanje simptoma osteoartritisa; v) povećanje motoričkih vještina ili pokretljivosti kod pacijenta s osteoartritisom; vi) inhibiranja degeneracije pokretljivosti kod pacijenta s osteoartritisom; vii) povećanje raspona pokreta u zahvaćenom zglobu subjekta koji ima osteoartritis; viii) smanjenje ukočenosti u zahvaćenom zglobu subjekta koji ima osteoartritis; ix) smanjenje sinovijalne upale kod subjekta; ili x) sprječavanje nastanka osteoartritisa, kod subjekta kojem je to potrebno, pri čemu se CNP varijanta primjenjuje intraartikularno.
2. CNP varijanta odabrana iz skupine koju čine SEQ ID NOs.: 1, 2, 22 i 43 do 47 za uporabu prema patentnom zahtjevu 1, naznačena time što je osteoartritis primarni osteoartritis ili sekundarni artritis.
3. CNP varijanta odabrana iz skupine koju čine SEQ ID NOs.: 1, 2, 22 i 43 do 47 za uporabu prema patentnom zahtjevu 2, naznačena time što se CNP varijanta primjenjuje nakon što je nastupila degeneracija hrskavice.
4. CNP varijanta odabrana iz skupine koju čine SEQ ID NOs.: 1, 2, 22 i 43 do 47 za uporabu prema patentnom zahtjevu 2, naznačena time što se CNP varijanta primjenjuje kao odgovor na ozljedu ili traumu zgloba.
5. CNP varijanta odabrana iz skupine koju čine SEQ ID NOs.: 1, 2, 22 i 43 do 47 za uporabu prema patentnom zahtjevu 4, naznačena time što se CNP varijanta primjenjuje unutar jednog mjeseca od ozljede ili traume zgloba.
6. CNP varijanta odabrana iz skupine koju čine SEQ ID NOs.: 1, 2, 22 i 43 do 47 za uporabu prema bilo kojem od prethodnih patentnih zahtjeva naznačena time što pripravak koji sadrži CNP varijantu daje 3 puta tjedno, dva puta tjedno, jednom tjedno ili jednom u dva tjedna.
7. CNP varijanta odabrana iz skupine koju čine SEQ ID NOs.: 1, 2, 22 i 43 do 47 za uporabu prema patentnom zahtjevu 1, naznačena time što se povećanje rasta hrskavice ili usporavanje degeneracije hrskavice opaža u zglobu subjekta.
8. CNP varijanta odabrana iz skupine koju čine SEQ ID NOs.: 1, 2, 22 i 43 do 47 za uporabu prema patentnom zahtjevu 7, naznačena time što je zglob odabran iz skupine koja se sastoji od koljena, ramena, lakta, prsta, šake, zapešća, kuka, vrata, kralježnice i donjeg dijela leđa.
9. CNP varijanta odabrana iz skupine koju čine SEQ ID NOs.: 1, 2, 22 i 43 do 47 za uporabu prema patentnom zahtjevu 1, naznačena time što se oštećenje ili rast hrskavice analizira smrću/gubitkom kondrocita, gubitkom proteoglikana (PG), ili gubitkom kolagena ili fibrilacijom.
10. CNP varijanta odabrana iz skupine koju čine SEQ ID NOs.: 1, 2, 22 i 43 do 47 za uporabu prema bilo kojem od prethodnih patentnih zahtjeva naznačena time što CNP varijanta nadalje sadrži farmaceutski prihvatljivu pomoćnu tvar, nosač ili razrjeđivač.
11. CNP varijanta odabrana iz skupine koju čine SEQ ID NOs.: 1, 2, 22 i 43 do 47 za uporabu prema patentnom zahtjevu 10, naznačena time što je CNP varijanta u liofiliziranoj formulaciji pripremljenoj od formulacije koja sadrži pufer limunska kiselina/citrat ili pufer octena kiselina/acetat koji ima pH od 4 do 6.
12. CNP varijanta odabrana iz skupine koju čine SEQ ID NOs.: 1, 2, 22 i 43 do 47 za uporabu prema bilo kojem od prethodnih patentnih zahtjeva naznačena time što dalje uključuje primjenu drugog sredstva, po izboru pri čemu je drugo sredstvo odabrano iz skupine koju čine protuupalno sredstvo, NSAID, kortikosteroid i hijaluronska kiselina.
13. CNP varijanta odabrana iz skupine koju čine SEQ ID NOs.: 1, 2, 22 i 43 do 47 za uporabu prema patentnom zahtjevu 1, naznačena time što je raspon pokreta zahvaćenog zgloba određen mjerenjem fleksije kuka, ekstenzije kuka, abdukcije kuka, adukcije kuka, fleksije koljena ili ekstenzije koljena.
14. CNP varijanta odabrana iz skupine koju čine SEQ ID NOs.: 1, 2, 22 i 43 do 47 za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što je identificirano da subjekt ima povećane razine najmanje jednog biomarkera povezanog s hrskavicom, po izboru pri čemu je najmanje jedan biomarker povezan s hrskavicom odabran iz skupine koja se sastoji od CNP, cGMP, propeptida kolagena tipa II i njegovih fragmenata, kolagena tipa II i njegovih fragmenata, osteokalcina, nuklearnog antigena proliferirajućih stanica (PCNA), propeptida prokolagena tipa I (PINP) i njegovih fragmenata, kolagena tipa I i njegovih fragmenata, i agrekan kondroitin sulfata.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562264682P | 2015-12-08 | 2015-12-08 | |
| PCT/US2016/065520 WO2017100400A2 (en) | 2015-12-08 | 2016-12-08 | Use of c-type natriuretic peptide variants to treat osteoarthritis |
| EP16852866.9A EP3386531B1 (en) | 2015-12-08 | 2016-12-08 | Use of c-type natriuretic peptide variants to treat osteoarthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211908T1 true HRP20211908T1 (hr) | 2022-03-04 |
Family
ID=59013378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211908TT HRP20211908T1 (hr) | 2015-12-08 | 2016-12-08 | Upotreba varijanti natriuretskog peptida c-tipa za liječenje osteoartritisa |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11202819B2 (hr) |
| EP (2) | EP3386531B1 (hr) |
| JP (1) | JP7104625B2 (hr) |
| KR (1) | KR20180088459A (hr) |
| CN (1) | CN108697766A (hr) |
| AU (2) | AU2016365751B2 (hr) |
| CA (1) | CA3007315A1 (hr) |
| DK (1) | DK3386531T3 (hr) |
| ES (1) | ES2901769T3 (hr) |
| HR (1) | HRP20211908T1 (hr) |
| HU (1) | HUE057083T2 (hr) |
| IL (1) | IL259690B2 (hr) |
| MX (1) | MX2018006986A (hr) |
| PL (1) | PL3386531T3 (hr) |
| PT (1) | PT3386531T (hr) |
| RU (2) | RU2759679C2 (hr) |
| WO (1) | WO2017100400A2 (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018008061A (es) | 2016-01-08 | 2018-08-23 | Ascendis Pharma Growth Disorders As | Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes. |
| AU2017205694B2 (en) | 2016-01-08 | 2022-05-26 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with low NPR-C binding |
| KR20180100624A (ko) | 2016-01-08 | 2018-09-11 | 아센디스 파마 그로우쓰 디스오더스 에이/에스 | 증가된 nep 안정성을 갖는 제어 방출성 cnp 작용제 |
| IL259658B2 (en) | 2016-01-08 | 2024-06-01 | Ascendis Pharma Growth Disorders As | Controlled-release CNP agonists with reduced side effects |
| AU2017205688C1 (en) | 2016-01-08 | 2022-03-10 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with carrier attachment at the ring moiety |
| CA3007982C (en) | 2016-01-08 | 2023-12-19 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with low initial npr-b activity |
| BR112019005351A2 (pt) | 2016-09-29 | 2019-06-11 | Ascendis Pharma Growth Disorders As | terapia combinada com agonistas de cnp de liberação controlada |
| CN112752556A (zh) * | 2018-04-27 | 2021-05-04 | 雷米生物科学公司 | 新的医疗装置、递送运载体及其制造 |
| CN117281783A (zh) * | 2019-02-11 | 2023-12-26 | 阿森迪斯药物生长障碍股份有限公司 | Cnp缀合物的干燥药物制剂 |
| WO2022240936A1 (en) * | 2021-05-11 | 2022-11-17 | Texas Tech University System | Targeted selenium conjugates as countermeasures for pathogenic viruses and cells |
| TW202334188A (zh) * | 2021-12-07 | 2023-09-01 | 美商拜奧馬林製藥公司 | Ｃｎｐ療法 |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| JP2809533B2 (ja) | 1991-01-31 | 1998-10-08 | 壽之 松尾 | Ｃｎｐ類似体ペプチド |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| IL142118A0 (en) | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
| US7642243B2 (en) * | 2004-03-31 | 2010-01-05 | Kazuwa Nakao | Method of treating arthritis and promoting growth of articular chondrocytes |
| JP4972403B2 (ja) * | 2004-03-31 | 2012-07-11 | 一和 中尾 | 身長増加用組成物 |
| CA2705603A1 (en) | 2007-11-21 | 2009-05-28 | Biomarin Pharmaceutical Inc. | Variants of c-type natriuretic peptide |
| PL2432489T3 (pl) * | 2009-05-20 | 2017-05-31 | Biomarin Pharmaceutical Inc. | Warianty peptydu natriuretycznego typu C |
| US9266939B2 (en) * | 2010-12-27 | 2016-02-23 | Alexion Pharmaceuticals, Inc. | Compositions comprising natriuretic peptides and methods of use thereof |
-
2016
- 2016-12-08 AU AU2016365751A patent/AU2016365751B2/en active Active
- 2016-12-08 JP JP2018530079A patent/JP7104625B2/ja active Active
- 2016-12-08 WO PCT/US2016/065520 patent/WO2017100400A2/en active Application Filing
- 2016-12-08 MX MX2018006986A patent/MX2018006986A/es unknown
- 2016-12-08 KR KR1020187019166A patent/KR20180088459A/ko not_active Application Discontinuation
- 2016-12-08 EP EP16852866.9A patent/EP3386531B1/en active Active
- 2016-12-08 HR HRP20211908TT patent/HRP20211908T1/hr unknown
- 2016-12-08 RU RU2018124600A patent/RU2759679C2/ru active
- 2016-12-08 HU HUE16852866A patent/HUE057083T2/hu unknown
- 2016-12-08 CN CN201680081329.2A patent/CN108697766A/zh active Pending
- 2016-12-08 US US15/779,049 patent/US11202819B2/en active Active
- 2016-12-08 RU RU2021132347A patent/RU2021132347A/ru unknown
- 2016-12-08 EP EP21202207.3A patent/EP4019038A3/en active Pending
- 2016-12-08 CA CA3007315A patent/CA3007315A1/en active Pending
- 2016-12-08 DK DK16852866.9T patent/DK3386531T3/da active
- 2016-12-08 ES ES16852866T patent/ES2901769T3/es active Active
- 2016-12-08 PL PL16852866T patent/PL3386531T3/pl unknown
- 2016-12-08 PT PT168528669T patent/PT3386531T/pt unknown
-
2018
- 2018-05-29 IL IL259690A patent/IL259690B2/en unknown
-
2021
- 2021-12-03 US US17/541,992 patent/US20220160836A1/en active Pending
-
2024
- 2024-03-21 AU AU2024201852A patent/AU2024201852A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016365751B2 (en) | 2023-12-21 |
| ES2901769T3 (es) | 2022-03-23 |
| US20190247467A1 (en) | 2019-08-15 |
| RU2018124600A (ru) | 2020-01-13 |
| IL259690A (en) | 2018-07-31 |
| AU2024201852A1 (en) | 2024-04-11 |
| JP2019505486A (ja) | 2019-02-28 |
| DK3386531T3 (da) | 2022-01-03 |
| KR20180088459A (ko) | 2018-08-03 |
| RU2021132347A (ru) | 2022-03-24 |
| EP3386531A2 (en) | 2018-10-17 |
| MX2018006986A (es) | 2018-09-05 |
| AU2016365751A1 (en) | 2018-06-21 |
| US11202819B2 (en) | 2021-12-21 |
| EP3386531B1 (en) | 2021-10-13 |
| EP4019038A3 (en) | 2022-09-28 |
| PT3386531T (pt) | 2021-12-29 |
| HUE057083T2 (hu) | 2022-04-28 |
| CA3007315A1 (en) | 2017-06-15 |
| PL3386531T3 (pl) | 2022-02-28 |
| IL259690B2 (en) | 2023-02-01 |
| EP4019038A2 (en) | 2022-06-29 |
| US20220160836A1 (en) | 2022-05-26 |
| CN108697766A (zh) | 2018-10-23 |
| RU2018124600A3 (hr) | 2020-01-13 |
| JP7104625B2 (ja) | 2022-07-21 |
| WO2017100400A3 (en) | 2017-10-26 |
| WO2017100400A2 (en) | 2017-06-15 |
| IL259690B (en) | 2022-10-01 |
| RU2759679C2 (ru) | 2021-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211908T1 (hr) | Upotreba varijanti natriuretskog peptida c-tipa za liječenje osteoartritisa | |
| JP2019505486A5 (hr) | ||
| Oddis et al. | A subluxing arthropathy associated with the anti‐Jo‐1 antibody in polymyositis/dermatomyositis | |
| HRP20210277T1 (hr) | Pripravak za kontroliranu stimulaciju jajnika | |
| HRP20140888T1 (hr) | Humana monoklonalna protutijela za humani il-4 | |
| RU2017102387A (ru) | Местное применение антитела к hsv | |
| PH12019501900A1 (en) | Treatment of hidradenitis suppurativa | |
| PE20212158A1 (es) | Composicion farmaceutica acuosa de anticuerpo anti-il17a y su uso | |
| Nassonova et al. | Eosinophilic fasciitis: review and report of six cases | |
| ES2579828T3 (es) | Composición para la prevención y el tratamiento de la artritis reumatoide | |
| Lu et al. | Effect of neuromuscular control training on frozen shoulder | |
| Suthar et al. | Orthopaedic aspect of anatomy and radiology of proximal femur | |
| WEBER et al. | Fibrous Replacement of the Deltoid Muscle: A Remediable Cause of Abduction Contracture of the Shoulder in Scleroderma. | |
| Khan et al. | Functional outcome following olecranon osteotomy approach for fixation of T/Y fractures of distal humerus | |
| CN204812197U (zh) | 一种老年人防摔骨折保护裤 | |
| CN202537785U (zh) | 一种新型婴儿纸尿裤 | |
| Rodríguez et al. | Unilateral generalized morphea: a case and literature review | |
| Banks et al. | Successful treatment of pansclerotic morphea with imatinib mesylate in a pediatric patient | |
| CN202236861U (zh) | 一种预防和治疗风湿病的护膝 | |
| Rawal et al. | A rare case of neglected paediatric elbow dislocation treated with open reduction in tertiary care rural hospital of Nepal | |
| Yusupov | Biomechanical criteria of orthopedic status of patients with dysplastic coxarthrosis (Crowe) IV before and after treatment | |
| Bytyçi et al. | Treatment of neonatal septic arthritis sequelae of hip: a case report | |
| Joseph et al. | Fractures in boys with Duchenne muscular dystrophy and their relationship to age | |
| Rojko et al. | Glivni artritisi | |
| PL426567A1 (pl) | Opatrunek medyczny kolagenowo-grafenowy |